Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme

Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent

FDA has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term